Document:

Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit 10.19

Confidential treatment requested

  LICENSE AGREEMENT
  No. 651-O1.LIC         

    THIS
AGREEMENT (the "Agreement"), made this 3rd day of February, 2000 (the "EFFECTIVE DATE"), is by and between the ARIZONA BOARD OF REGENTS, a body corporate of the
State of Arizona, acting on behalf of and for ARIZONA STATE UNIVERSITY, of Tempe, Arizona ("ASU") and Seattle Genetics, Inc., a corporation organized under the laws of Delaware having its
principal place of business located at 22215 26th Avenue SE, Bothell, Washington 98021 ("LICENSEE"). 

RECITALS  

	A.
	A
certain invention, generally characterized as a drug known under the name "Auristatin E", hereinafter referred to as the "TECHNOLOGY", was made in the course of research at ASU by
G. Robert Pettit and Jozsef Barkoczy and are and will be covered by ASU's PATENT RIGHTS, as defined below.

	B.
	The
National Cancer Institute sponsored part of the development of the TECHNOLOGY (as defined below) and as a consequence this license is subject to overriding obligations to the
Federal Government as set forth in 35 U.S.C. 200-212 and applicable governmental implementing regulations.

	C.
	The
LICENSEE is a "small business firm" as defined in 15 U.S.C. 632.

	D.
	ASU
represents and warrants that it has the right to grant licenses to make, have made, use and sell products or services covered by ASU's PATENT RIGHTS under such patent rights,
together with any patents which have issued and which may yet issue on it.

	E.
	ASU
is desirous that the TECHNOLOGY be developed and utilized to the fullest extent so that the benefits can be enjoyed by the general public; and

	F.
	The
LICENSEE is desirous of obtaining certain rights from ASU for the commercial development, use, and sale of products or services covered by ASU's PATENT RIGHTS, and ASU is
willing to grant such rights on the terms and conditions set forth herein. 

  AGREEMENT         

DEFINITIONS  

    1.1.   "AFFILIATE"
means any corporation or other business entity that, directly or indirectly, controls, is controlled by or is under control with
LICENSEE where control shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or participating shares entitled to vote for
the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to direct
the management and policies of such entity; provided, however, that in any country where the local law shall not permit foreign equity participation of at least 50%, then an "AFFILIATE" shall include
any company in which the LICENSEE shall own or control, directly or indirectly, the maximum percentage of such outstanding stock or voting rights permitted by local law. 

	[*]
	Confidential treatment requested

1

    1.2.   "ASU's
PATENT RIGHTS" shall mean patent rights to certain subject matter, which is included in the following: 

Under ASU Case No. 651:

U.S.
Patent No. 5,635,483 entitled "Tumor Inhibiting Tetrapeptide Bearing Modified Phenethyl Amides". 

For
the purposes of this Agreement, only those compounds taught in the above named patent and identified as stereoisomers of a compound commonly referred to as "Auristatin E" are included in this
license and the grant of rights described in Article 2 of this Agreement shall pertain only to the following: 

Auristatin E, Compound No. 1S2R 

Auristatin E, Compound No. 1R2R 

Auristatin E, Compound No. 1S2S 

Auristatin E, Compound No. 1R2S  

Each of which falls within the general structure shown below:

   

and
any corresponding extensions or foreign applications or patents. 

    1.3.   "INVENTOR"
shall, for the purposes of the Agreement, mean Dr. George R. Pettit and Jozsef Barkoczy whose names appear on the patent
described by ASU's PATENT RIGHTS. 

    1.4.   "KNOW-HOW"
shall mean all technical data, information, materials and technical expertise that relates to TECHNOLOGY, including without
limitation, chemical and physical data and techniques, clinical data, medical uses, product forms, formulations, and specifications. 

    1.5.   "LICENSED
FIELD OF USE" shall mean all uses of LICENSED PRODUCTS or LICENSED METHODS. 

    1.6.   "LICENSED
METHOD" shall mean any method, procedure, process or other subject matter whose use or practice would constitute, but for any license
granted to LICENSEE hereunder, an infringement of any VALID CLAIM contained in ASU's PATENT RIGHTS, as defined herein. 

    1.7.   "LICENSED
PRODUCT' shall mean any material, composition, composition of matter, compound, device or embodiment the manufacture, use or sale of
which would constitute, but for the license granted to the LICENSEE pursuant to this Agreement, an infringement of any VALID CLAIM contained in ASU's PATENT RIGHTS, as defined herein. For the purposes
of this Agreement, 

2

LICENSED PRODUCT shall include combinations of chemical compounds in which a single agent such as Auristatin E is combined with another compound such as an antibody. 

    1.8.   "NET
SALES" means the total of the gross invoice prices of LICENSED PRODUCTS sold by the LICENSEE, an AFFILIATE, or a SUB-LICENSEE,
less the sum of the following actual and customary deductions where applicable: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed upon or
levied with respect to any sale of LICENSED PRODUCTS; transportation and insurance charges; and allowances or credits because of rejections or returns or uncollectible amounts. Transfers to an
AFFILIATE or SUB-LICENSEE for end use by the AFFILIATE or SUB-LICENSEE shall be treated as NET SALES. 

    1.9.   "SUB-LICENSEE"
shall mean any corporation or other business entity to which the LICENSEE has granted a sub-license under
the ASU's PATENT RIGHTS, as permitted herein. 

    1.10.  "TECHNOLOGY"
shall mean certain inventions relating to Auristatin E, which were made in the course of research at ASU by Drs. G. Robert Pettit,
and Jozsef Barkoczy which are covered by ASU's PATENT RIGHTS, as defined herein. 

    1.11.  "TERM"
shall mean the period of time commencing on the EFFECTIVE DATE and continuing until the [*]. 

    1.12.  "TERRITORY"
shall mean world-wide. 

    1.13.  "VALID
CLAIM" shall mean a claim in any issued unexpired United States patent and a pending claim in any corresponding foreign patent application
included in ASU's PATENT RIGHTS which has not been held unpatentable or invalid or unenforceable by a decision of a court or other competent authority, which is not appealable or not appealed within
the time allowed for appeal, and which has not been admitted to be invalid through reissue or disclaimer or otherwise and which is not subject to an interference claim. 

2.  GRANT  

    2.1.   ASU
hereby grants to LICENSEE an exclusive license in the TERRITORY and in the LICENSED FIELD OF USE, which shall include the right to grant
sub-licenses, under ASU's PATENT RIGHTS, as specified in Paragraph 1.1, to develop, have developed, make, have made, market, import, sell, and otherwise use LICENSED PRODUCTS and to
practice the LICENSED METHODS under ASU's PATENT RIGHTS. 

    2.2.   Except
as otherwise provided herein, the rights granted in Paragraph 2.1 shall extend for the TERM of this Agreement. 

    2.3.   The
license granted hereunder may be subject to all the applicable provisions of any Licenses to the United States Government executed by ASU. The
license granted hereunder is subject to the
overriding obligations to the U.S. Government set forth in 35 U.S.C. 200-2 12 and applicable governmental implementing regulations. 

    2.4.   ASU
expressly reserves the right to use the TECHNOLOGY for educational and non-commercial research purposes. 

    2.5.   This
Agreement and grant of license hereunder are subject to the terms and conditions contained throughout this agreement including the Licensee's
specific diligence obligations specified in Article 8. 

3.  SUB-LICENSES  

    3.1.   ASU
also hereby grants to the LICENSEE the right to issue sub-licenses in the TERRITORY to SUB-LICENSEES to develop, have
developed, make, have made, market, import, sell and otherwise use LICENSED PRODUCTS and to practice the LICENSED METHODS, provided the 

3

LICENSEE has current rights thereto under this Agreement. To the extent applicable, such sub-licenses shall include all of the rights of and obligations due to ASU (and, if applicable, the
United States Government) that are contained in this Agreement including without limitation those obligations set forth in Article 25.

    3.2.   The
LICENSEE shall provide ASU with a copy of each sub-license issued within thirty (30) days after execution; collect and
guarantee payment of all royalties due ASU from SUB-LICENSEES; and deliver all reports due ASU from SUB-LICENSEES, as provided herein. 

    3.3.   Except
as otherwise provided in Paragraph 16.4 hereof, upon termination of this Agreement for any reason, ASU, at its sole discretion, may
determine whether any or all sub-licenses are to be canceled or assigned to ASU. 

4.  LICENSE ISSUE FEE AND MILESTONE PAYMENTS  

    The LICENSEE agrees to pay to ASU a non-refundable Issue Fee of $[*] within 10 days of the EFFECTIVE DATE. 

5.  PAYMENTS AND ROYALTIES  

    5.1.  License Maintenance Payments:  

    5.1.1.  The
LICENSEE shall pay to ASU an annual maintenance fee beginning at $[*] and increasing by annual increments of
$[*] each year up to a maximum of $[*] per year. For example, the [*] annual maintenance fee will be
$[*]; the [*] will be $[*]; the [*] will be $[*]; the
[*] will be $[*] and the [*] will be $[*] and will continue each year thereafter at the
$[*] rate. 

    5.1.2.  Such
annual maintenance fee payments shall be due and payable each year until a "New Drug Approval" (NDA) is received by the US Food and Drug
Administration. No maintenance fee shall be due during the years following receipt of the NDA. 

    5.1.3.  The
first such annual maintenance fee payment shall be due and payable on the first year anniversary of the EFFECTIVE DATE. 

    5.1.4.  Commencing
with the second annual maintenance fee, the annual maintenance fee shall be payable in two equal installments. The first installment
shall be due and payable on the six-month anniversary of the EFFECTIVE DATE and the second installment shall be due and payable on the one-year anniversary of the EFFECTIVE
DATE. 

    5.2  Milestone Payments  

    5.2.1.  The
LICENSEE shall make milestone payments to ASU upon the achievement of certain clinical development milestones according to the schedule,
below: 

    5.2.2.  Upon
initiation of the first Phase III clinical study in which the LICENSED PRODUCT is a single agent such as Auristatin E: 

  $[*]

    5.2.3.  Upon
initiation of the first Phase III clinical study in which the LICENSED PRODUCT that constitutes a combination of a single agent such as
Auristatin E and another compound such as an antibody: 

  $[*] 

    5.2.4.  Upon
FDA approval of an NDA for a LICENSED PRODUCT that is a single agent such as Auristatin E: 

  $[*]

4

    5.2.5.  Upon
FDA approval of an NDA for a LICENSED PRODUCT that constitutes a combination of a single agent such as Auristatin E and another compound
such as an antibody: 

  $[*] 

    5.3.  Earned Royalties:  

    5.3.1.  The
LICENSEE shall pay to ASU an EARNED ROYALTY of [*]% of the NET SALES of all LICENSED PRODUCTS that utilize a process
or composition of matter covered by claims contained in ASU's PATENT RIGHTS and that constitute a single agent, i.e.: Auristatin E. 

    5.3.2.  The
LICENSEE shall pay to ASU an EARNED ROYALTY of [*]% of the NET SALES of all LICENSED PRODUCTS that utilize a process
or composition of matter covered by claims contained in ASU's PATENT RIGHTS and that constitute a combination of a single agent such as Auristatin E and another compound such as an antibody. 

    5.3.3.  The
LICENSEE shall pay to ASU an earned royalty ("EARNED ROYALTY") in accordance with the rules specified in Paragraphs 5.4 through 5.14.
LICENSEE's and/or SUB-LICENSEE's obligation to pay EARNED ROYALTIES shall commence with the first sale of any LICENSED PRODUCT and will continue as long as the LICENSEE and/or
SUB-LICENSEES are selling any LICENSED PRODUCT throughout the TERM and in accordance with the sub-paragraphs, below: 

    5.4.  Minimum Annual Royalty:

    The
LICENSEE shall pay to ASU a minimum annual royalty of $[*] for the life of VALID CLAIMS of ASU's PATENT RIGHTS (the "Minimum Annual Royalty"), beginning in
the year of LICENSEE's first receipt of marketing approval for a LICENSED PRODUCT from the US Food and Drug Administration ("US FDA") or any other analogous worldwide regulatory agency. LICENSEE shall
account to ASU and pay royalties to ASU semi-annually within forty-five (45) days after the end of each calendar half-year for the just preceding calendar
half-year. Concurrent with the final royalty payment, due on February 15 following any year, LICENSEE shall make an additional payment if necessary in order to meet its obligation
to make minimum royalty payments for that year. 

    5.5.   For
sales of LICENSED PRODUCTS to an AFFILIATE of LICENSEE at a reduced price from that customarily charged to an unrelated third party, the
royalty paid to ASU shall be based on the NET SALES of such LICENSED PRODUCTS by the AFFILIATE to the AFFILIATE'S customers. Where the LICENSEE sells LICENSED PRODUCTS for end use to itself or an
AFFILIATE, such sale shall be considered a sale at list price, and ASU shall be entitled to receive a royalty in accordance
with this Article based on such list price. Each reference to the LICENSEE shall be meant to include its AFFILIATES. 

    5.6.   In
the event LICENSEE sells LICENSED PRODUCTS to a SUB-LICENSEE for end use by that SUB-LICENSEE, such sale shall be
considered a sale at list price, and ASU shall be entitled to receive a royalty in accordance with this Article based on such list price. If no such list price is available, such sale shall be
considered a sale at a commercially reasonable price between arm's length parties, as determined in good faith by LICENSEE and based on its sales price to other arm's length third parties, if
available. 

    5.7.   Article 1
defines ASU's PATENT RIGHTS and LICENSED PRODUCTS so that royalties are payable on LICENSED PRODUCTS covered by a Valid Claim.
EARNED ROYALTIES shall be due on LICENSED PRODUCTS in each country where relevant ASU's PATENT RIGHTS exist, for the duration of VALID CLAIMS of such ASU'S PATENT RIGHTS in such country. EARNED
ROYALTIES shall accrue to ASU when LICENSED PRODUCTS are invoiced, or if not invoiced, when delivered to a third party and shall be paid as set forth below. 

5

    5.8.   Commencing upon the first commercial sale of a LICENSED PRODUCT, the LICENSEE shall pay EARNED ROYALTIES accruing to ASU on a
semi-annual basis on or before the following dates of each calendar year: 

	•
	[*]

	•
	[*]

    5.9.   Each
payment pursuant to this Article 5 shall be for EARNED ROYALTIES that accrued within the
LICENSEE's most recently completed calendar half-year and shall be accompanied by a royalty report. Such reports shall indicate for the relevant calendar half-year the NET
SALES of the LICENSED PRODUCT manufactured or sold by LICENSEE, its AFFILIATES and its SUB-LICENSEES with respect to which payments are due, and the amount of those payments. If no payment
is due for any period, LICENSEE shall so report. 

    5.10.  All
moneys due ASU shall be payable in United States funds collectible in Tempe, Arizona. When LICENSED PRODUCTS are sold for moneys other than
United States dollars, the EARNED ROYALTIES shall first be determined in the foreign currency of the country in which such LICENSED PRODUCTS were sold and then converted into equivalent United States
funds. The exchange rate for such conversion shall be that rate quoted in The Wall Street Journal on the last business day of the reporting period. 

    5.11.  Royalties
earned with respect to sales occurring in any country outside the United States shall not be reduced by any taxes, fees, or other
charges imposed by the government of such country on the remittance of royalty income. Notwithstanding the foregoing, all payments made by the LICENSEE in fulfillment of ASU's tax liability in any
particular country shall be credited against Earned Royalties or fees due ASU for that country and shall be reported to ASU along with payment of EARNED ROYALTIES, net of any such amount. 

    5.12.  If
at any time legal restrictions prevent the prompt remittance of part or all royalties by the LICENSEE with respect to any country where a
LICENSED PRODUCT is sold, royalty payments attributable to sales in that country shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect,
all royalties that ASU would have been entitled to but for the prohibition shall be deposited or transmitted to the extent allowable. 

    5.13.  If
any patent or any claim included within ASU's PATENT RIGHTS is held invalid in a final decision by a court of competent jurisdiction and last
resort and from which no appeal has or can be taken, all obligation to pay royalties hereunder based on such patent or claim or any patentably indistinct claim shall cease as of the date of such final
decision. Royalty payments shall be suspended during any period in which the PATENT RIGHTS are subject to any interference or other proceeding disputing the validity of the PATENT RIGHTS. Once such
interference or other proceeding is concluded and such disputed claims within ASU's PATENT RIGHTS are upheld, LICENSEE shall make a royalty payment to ASU to cover the royalty due on all NET SALES
during the suspension and continuing royalty payments and obligations to ASU shall be resumed as though no interference or other proceeding ever took place. 

    5.14.  No
royalties shall be collected or paid on LICENSED PRODUCTS sold to the account of the U.S. Government, any agency thereof, or any state or
domestic municipal government as provided for in any License to the Government. 

6.  PATENT EXPENSES and PATENT PROSECUTION AND MAINTENANCE  

    6.1.   The
costs of preparing, filing, prosecuting and maintaining all United States and foreign patent applications and issued patents from and after
the EFFECTIVE DATE shall be borne by ASU. These costs include any patent prosecution costs that are incurred for appeals, re-examination, re-issue, interferences, or
inventorship determinations as well as the maintenance of all resulting patents. ASU 

6

shall prepare and deliver to LICENSEE a report setting forth the countries in which it has filed and intends to file applications with respect to ASU's PATENT RIGHTS. LICENSEE may request ASU in
writing to file applications in additional countries. LICENSEE shall be responsible for any incremental costs incurred by ASU for any countries added in accordance with the foregoing after ASU's
receipt of such request from LICENSEE. 

    6.2.   All
patents comprising or including ASU's PATENT RIGHTS shall be held in the name of ASU and shall be obtained and maintained using counsel who
are on ASU's list of officially approved intellectual property counsel, and who are approved by LICENSEE, such approval not to be unreasonably withheld. 

    6.3.   ASU
shall use reasonable efforts to obtain, file, prosecute and maintain the United States and foreign patents comprising ASU's PATENT RIGHTS at
ASU's sole discretion. ASU agrees to consult with LICENSEE and give good faith consideration to LICENSEE's comments regarding such patent prosecution and related proceedings to the extent related to
the TECHNOLOGY. It is understood by LICENSEE that ASU counsel takes instructions only from ASU. 

    6.4.   The
LICENSEE shall have the right to request that ASU obtain patent protection on the TECHNOLOGY in foreign countries if available and if it so
desires. The LICENSEE shall notify ASU within seven (7) months of the filing of the corresponding United States application of its decision to obtain additional foreign patents. This notice
concerning foreign filing shall be in writing, shall identify the countries desired, and shall reaffirm the LICENSEE's obligation to underwrite the incremental costs thereof. 

    6.5.   ASU
shall use all reasonable efforts to amend any patent application to include claims reasonably requested by the LICENSEE to protect the
products contemplated to be sold under this Agreement, or to cover competitive products as long as such amendments, in the opinion of ASU's patent counsel will not jeopardize issuance of a patent. ASU
shall pursue all claims of improper inventorship regarding any patent or patent application, which is or would be subject to the licenses granted hereunder as reasonably requested by LICENSEE and at
LICENSEE's expense. 

    6.6.   ASU's
obligation to prosecute any patent application shall cease at such time when ASU is advised by counsel that such patent application has been
rejected and an appropriate appeal procedure must be pursued in order to gain issuance of the patent; or if an order for reexamination is issued by the patent office; or if an interference is
declared; or if a patent reissuance is required or requested by the LICENSEE. If, however, upon notification by ASU, LICENSEE re-affirms its obligation in writing that LICENSEE will
reimburse ASU for the costs involved in such appeals process, ASU will proceed with the necessary action. 

    6.7.   ASU
shall promptly advise a LICENSEE of the grant, lapse, revocation, surrender or invalidation of any ASU PATENT RIGHT. ASU shall not abandon or
irrevocably limit the scope of any ASU PATENT RIGHT in any country without the prior written consent of LICENSEE. 

7.  TECHNICAL INFORMATION and DUE DILIGENCE  

    7.1.   Within
60 days of the EFFECTIVE DATE, the ASU Cancer Research Institute shall supply one-hundred milligrams (100 mg.) of
Auristatin E to the LICENSEE. 

    7.2.   Within
60 days of the EFFECTIVE DATE, ASU shall transfer to LICENSEE all KNOW-HOW, preclinical data, assays and associated
materials, protocols, procedures and any other information in ASU's possession or control, necessary or desirable to develop the TECHNOLOGY. 

    7.3.   Each
party, for itself and any SUB-LICENSEE'S, undertakes during the TERM of this Agreement, and for a period of  5 years following the termination of this Agreement, to hold in confidence and not to use
or disclose to any third party, except as
permitted herein, the 

7

TECHNOLOGY and KNOW-HOW received from the other party. This obligation shall not apply to the portion(s) of TECHNOLOGY and KNOW-HOW which: 

    7.3.1.  was
known to the receiving party or any of its SUB-LICENSEES prior to its receipt by the receiving party, and can be so proved by
written or electronic records; or 

    7.3.2.  is
received at any time by the receiving party or its SUB-LICENSEES in good faith from a third party lawfully in possession of it
and having the right to disclose the same, and can be so proved by written or electronic records; or 

    7.3.3.  is
as of the date of receipt by the receiving party in the public domain or subsequently enters the public domain other than by reason of acts
or omissions of the employees or agents of the receiving party or its SUB-LICENSEES, and can be so proven by written or electronic records; or is independently developed by the receiving
party without any reference to the TECHNOLOGY or KNOW-HOW, and can be so proved by written or electronic records. 

    7.4.   LICENSEE
and its SUB-LICENSEES may use and discuss the TECHNOLOGY and KNOW-HOW received from ASU in connection with
applying for and securing necessary governmental authorization for the lawful marketing of LICENSED PRODUCTS in the TERRITORY; and in connection with LICENSEE's financing activities. 

    7.5.   Notwithstanding
the provisions of Paragraph 7.3, ASU reserves the right to publish information of scientific importance, including any
TECHNOLOGY and KNOW-HOW; provided, however, that (1) the TECHNOLOGY and KNOW-HOW or the material part of it shall, prior to such publication, have been made the subject
of a United States patent application, or (2) LICENSEE, upon review as provided for herein, shall have declined to comment within the prescribed period of time. ASU shall furnish LICENSEE with
a copy of every relevant publication by ASU pursuant to this Article, prior to publication of the information. LICENSEE shall have 30 days from receipt of the intended publication to indicate
to ASU any reasonable revisions or deletions it deems necessary to protect its proprietary rights. Title to any copyrightable material, first produced or composed by one party, shall remain with that
party; provided an irrevocable, royalty-free right to reproduce, translate and use the copyrighted material for purposes of this Agreement shall be granted to the other party. 

8.  DUE DILIGENCE AND MARKETING OBLIGATIONS  

    8.1.   The
LICENSEE, upon execution of this Agreement, shall diligently proceed with the development, manufacture and sale of LICENSED PRODUCTS and shall
diligently endeavor to market the same within a reasonable time after execution of this Agreement and in quantities sufficient to meet the market demands. LICENSEE shall promptly notify ASU in writing
of the commencement of such marketing. 

    8.2.   LICENSEE
shall promptly advise ASU in writing if it decides (i) not to market any LICENSED PRODUCT in any country, (ii) to
discontinue the marketing of such LICENSED PRODUCT in any country, or (iii) to not resume the marketing of such LICENSED PRODUCT in any country following expiration. This notice shall, unless
LICENSEE is (a) developing another LICENSED PRODUCT which is either superior, based on data available at that time, or is at the same or a later stage of development than the abandoned LICENSED
PRODUCT or (b) marketing another LICENSED PRODUCT for the same indication in such country at such time, serve to terminate this Agreement as to that LICENSED PRODUCT and that country. 

    8.3.   The
Parties shall promptly advise one another of any confirmed instance which comes to either party's attention of severe or unexpected reactions
from the use of TECHNOLOGY or any LICENSED PRODUCT. 

    8.4.   LICENSEE
shall, in a manner consistent with the effort devoted to products of the same or similar potential of its own development, prepare and
file or cause to be prepared and filed all 

8

necessary applications to obtain approval for LICENSED PRODUCTS in the name of LICENSEE or its AFFILIATES or SUB-LICENSEES from any necessary governmental authorities. 

    8.5.   LICENSEE
shall in the performance of any investigation, testing and solicitation of government approvals pertaining to the use of the TECHNOLOGY,
exercise at least the same degree of diligence which any reasonable and prudent manufacturer exercises in the investigation, testing and solicitation of government approvals for an invention of
similar class or utility invented by employees of and owned by the manufacturer. 

    8.6.   The
LICENSEE agrees to the following scientific and clinical development requirements. 

    8.6.1.  Perform
[*] on Auristatin E and complete same no later than [*]. 

    8.6.2.  [*]
with Auristatin E and complete same no later than [*]. 

    8.6.3.  Perform
[*] and complete same no later than [*]. 

    8.6.4.  Perform
[*] on Auristatin E and/or Auristatin E monoclonal antibody-drug conjugates
[*] and complete same no later than [*]. 

    8.6.5.  Perform
[*] on Auristatin E and/or Auristatin E monoclonal antibody-drug conjugates that
[*] and complete same no later than [*]. 

    8.6.6.  [*]
of Auristatin E and/or Auristatin E monoclonal-drug conjugates [*] and complete
same no later than [*]. 

    8.6.7.  [*]
on Auristatin E or Auristatin E monoclonal antibody-drug conjugates that [*] and
complete same no later than [*]. 

    8.6.8.  If
an IND Application is approved, initiate and conduct or have conducted at least [*] no later than
[*]. 

    8.7.   LICENSEE
shall meet the reasonably anticipated market demand for LICENSED PRODUCTS following commencement of marketing and during the TERM of this
Agreement. 

    8.8.   If
LICENSEE fails to meet any of the above requirements as set forth in Paragraphs 8.6.1 through 8.6.8, then ASU shall have the right to notify
LICENSEE of ASU's belief in writing that LICENSEE has failed to meet any such specific obligation with respect to any specified LICENSED PRODUCT(S) and to request LICENSEE to undertake immediate
remedial action. If the parties disagree as to any such failure, either may bring the matter up for arbitration in Maricopa County, Arizona upon sixty (60) days prior written notice under the
then prevailing rules of the American Arbitration Association for adjudication. If, during the arbitration process, it is determined that LICENSEE has not acted diligently with respect to such
LICENSED PRODUCT(S), then LICENSEE has the right to undertake remedial action. If the LICENSEE fails to do so, within a time deemed reasonable by the arbitrator, LICENSEE'S rights under this
Agreement(s) may be terminated by ASU with respect to the relevant LICENSED PRODUCT(S) pursuant to Paragraph 16.1. 

9.  REPORTS  

    9.1.   Beginning
on [*] and thereafter with each royalty report provided for in Paragraph  5.9, LICENSEE shall submit to ASU a progress report covering LICENSEE'S activities related to the testing and development of all
LICENSED PRODUCTS~
along with the obtaining of the governmental approvals necessary for marketing of LICENSED PRODUCTS. The LICENSEE shall make these progress reports for each LICENSED PRODUCT until the first commercial
sale of that LICENSED PRODUCT occurs in the United States. 

    9.2.   The
progress reports submitted under Paragraph 9.1 shall include, but not be limited to, the following topics: 

	•
	summary
of work completed 

9

	•
	key
scientific discoveries

	•
	summary
of work in progress

	•
	current
schedule of anticipated events or milestones 

    9.3.   At
the request of ASU from time to time, LICENSEE will provide information necessary to confirm the large/small entity status (as defined by the
United States Patent and Trademark Office) of itself and its SUB-LICENSEES and AFFILIATES. 

    9.4.   The
LICENSEE shall report to ASU the date of first commercial sale of a LICENSED PRODUCT in each country. 

    9.5.   LICENSEE
shall keep, and it shall cause its SUB-LICENSEES to keep, accurate records in sufficient detail to enable the payments due
under Article 5 to be determined for a period of 3 years following the end of the accounting period to which the information pertains. Upon the
request of ASU, LICENSEE and its SUB-LICENSEES shall permit an independent certified public accountant selected by ASU to have access, once in each calendar year during regular business
hours and upon reasonable notice to LICENSEE, to those records of LICENSEE and its SUB-LICENSEES as may be necessary or desirable to verify the accuracy of the reports made during the
previous calendar year. Should the audit reveal a discrepancy of more than 5% between the payment reported and the payment actually due to ASU, LICENSEE
shall pay all fees and expenses incurred in conducting the audit; otherwise ASU shall pay the fees and expenses incurred in conducting the audit. 

10.  WARRANTY  

    ASU warrants and represents that except for the possible government interest disclosed above, it has the full right and power to grant the license described in
Article 2, that it will take no action to negate this right and power and shall take all actions within its control to maintain this right and power and that it has no knowledge of any
outstanding undisclosed agreements, assignments, or encumbrances inconsistent with the provisions of this Agreement other than as expressly set forth herein. ASU makes no other representation or
warranty, express or implied, and ASU assumes no liability with respect of any infringement of any patent or other right of third parties due to LICENSEE's activities under the LICENSE granted
hereunder and ASU assumes no liability with regard to any claim, specious or otherwise, arising out of alleged side effects or any other alleged performance defect arising out of the use or misuse of
the LICENSED PRODUCTS. 

11.  PATENT ENFORCEMENT  

    11.1.  If
at any time during the TERM of this Agreement either party shall become aware of any infringement or threatened infringement of any of ASU's
PATENT RIGHTS, such party shall give immediate notice of it to the other party. If the infringement relates to the TECHNOLOGY, then LICENSEE shall have the first right to settle any alleged
infringement of ASU's PATENT RIGHTS. ASU shall have the first right to settle any alleged infringement of ASU's PATENT RIGHTS that does not relate to the TECHNOLOGY.. Each party shall give reasonable
assistance to the other party in connection with settling any alleged infringement and shall have the right to join in any infringement or enforcement action at its own expense. 

    11.2.  If
the party having the first right to take action under Section 11.1 is not able or willing to take action against an infringer as set
forth above, the other party shall have the right at any time following one hundred twenty (120) days of receipt of notice of the alleged infringement, to at its or their own expense take
action against the infringer. ASU shall permit, if legally necessary, the use of its name and shall execute any documents and do any acts as may be reasonably necessary for the purpose of taking
action. Any recovery received by the party taking action against an infringer pursuant to this Paragraph shall be retained for the benefit of such party, provided that in the case of LICENSEE taking
such action, royalties specified in Article 5 shall be paid to ASU on that portion of any recovery 

10

remaining after reimbursement of all of LICENSEE'S expenses hereunder and in the case of ASU taking such action, ASU shall pay to LICENSEE the amount of any damages for injury to LICENSEE or its
SUBLICENSEES resulting from the infringement. 

    11.3.  If
LICENSEE, its AFFILIATES or SUB-LICENSEES must pay royalties or license fees in any country to third parties under one or more
valid claims of a dominant patent to enable LICENSEE, its AFFILIATES or SUB-LICENSEES to use the inventions of the ASU's PATENT RIGHTS, those payments shall be credited against LICENSEE's
royalty obligations to ASU hereunder for sales in that country where a valid claim of a dominant patent exists to the extent of payments of royalties or license fees actually made to third parties by
LICENSEE, its AFFILIATES and SUB-LICENSEES. 

    11.4.  After
an initial determination by a court or tribunal that a claim or claims of any of ASU's PATENT RIGHTS is invalid, LICENSEE shall place all
royalties due by virtue of such ASU PATENT RIGHT in an interest-bearing escrow account until a decision by a court of last resort. If the court of last resort reverses the initial determination,
LICENSEE shall cause to be paid to ASU all amounts in escrow plus accrued interest within thirty (30) days after receipt of the determination of the court of last resort. If the court of last
resort upholds the initial determination, LICENSEE shall receive all amounts in escrow, plus accrued interest. 

    11.5.  Each
party agrees to use its best efforts whenever a protective order is to be entered with a court of competent jurisdiction, to have the order
permit at least one counsel from each party access to information provided under the protective order without restriction. 

12.  COMMUNICATION  

    Any payment, notice, or other communication required or permitted to be made or given to either party pursuant to this Agreement shall be sufficiently made or
given on the date of mailing if sent to the party by certified or registered mail, postage prepaid, addressed to it at its address set forth or to such other address as it shall be designated by
written notice to the other party as follows: 

In
the case of ASU:

Office of Technology Collaborations & Licensing

Office of the Vice Provost for Research

Arizona State University

P. 0. Box 873511

Tempe, AZ 85287.3511

USA

Attn: Director

In the case of LICENSEE:

Seattle Genetics, Inc.

22215 26th Avenue, SE

Bothell, Washington 98021

Attn: Chief Executive Officer 

13.  ASSIGNMENTS  

    This Agreement shall not be assignable by either party without the prior written consent of the other party except to an AFFILIATE or to a successor in
ownership of all or substantially all of the business assets to which this Agreement pertains and then only if such successor shall expressly assume in writing the performance of all the terms and
conditions of this Agreement which are to be performed by the assigning party. 

11

14.  TECHNICAL ASSISTANCE  

    14.1.  At
LICENSEE's written request, ASU shall: 

    14.1.1.  permit
representatives from LICENSEE and its SUB-LICENSEES to visit the facilities of ASU for the purpose of personally observing
the practice and testing of TECHNOLOGY or the production of LICENSED PRODUCTS, and 

    14.1.2.  arrange
for its or its AFFILIATES' representatives to visit the facilities of LICENSEE, or its SUB-LICENSEES as may be designated
by LICENSEE to provide LICENSEE, or its SUB-LICENSEES any technical assistance and advice as LICENSEE, and its SUB-LICENSEES may reasonably require in connection with the
production, packaging, inspecting, and testing of TECHNOLOGY and the LICENSED PRODUCTS or the LICENSED METHODS. 

    14.2.  LICENSEE
shall give ASU reasonable prior notice of the visits or required assistance referred to in Paragraphs 14.1.1 and 14.1.2 above and the
visits shall be of reasonable duration and made at reasonable times during regular business hours. LICENSEE and its SUB-LICENSEES shall bear the entire cost of the visits made pursuant to
Paragraph 14.1.1 and shall promptly reimburse ASU and its AFFILIATES for all reasonable salary, travel, and other expenses actually incurred by ASU and its Affiliates' representatives in the
course of the visits made to LICENSEE's and its SUB-LICENSEES' facilities pursuant to Paragraph 14.1.2. 

15.  PATENT MARKING  

    The LICENSEE shall mark all LICENSED PRODUCTS made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable
patent marking laws. 

16.  TERMINATION  

    16.1.  Material
failure by ASU or LICENSEE to comply with any of the material obligations and conditions contained in this Agreement (a "Default") shall
entitle the non-Defaulting party to give to the party in Default, written notice requiring it to cure the Default. If the Default is not cured or, if in the non-Defaulting
party's judgment, substantial steps have not been taken to cure the Default, within 90 days after the receipt of the notice by the Defaulting party, the non-Defaulting party shall
be entitled (without prejudice to any of its other rights conferred on it by this Agreement) to terminate this Agreement in whole or in part by giving notice to take effect immediately upon receipt by
the party in Default; provided, however, that with respect to a Default by LICENSEE under Paragraph 8.6., ASU's termination right hereunder shall only apply with respect to the LICENSED
PRODUCT(S) which is the subject of the Default. If the parties disagree as to the existence of any Default, such matter shall be resolved prior to any termination hereunder by arbitration to be
conducted in Maricopa County, Arizona upon 60 days prior written notice under the then prevailing rules of the American Arbitration Association. The right of either party to terminate this
Agreement shall not be affected in any way by its waiver of, or failure to take action with respect to, any previous Default. 

    16.2.  if
one of the parties shall voluntarily or involuntarily go into liquidation or bankruptcy, make an assignment for the benefit of creditors, or
have a receiver or a trustee appointed for its properties, the other party shall be entitled to terminate this Agreement immediately upon written notice to that party. 

    16.3.  LICENSEE
may terminate this Agreement with respect to such LICENSED PRODUCT or ASU PATENT RIGHT upon 30 days prior written notice with no
further obligation to ASU except for the payment of any fees which came due or royalties accrued up until the date of termination. 

12

    16.4.  Upon any termination of this Agreement, any SUB-LICENSEE then in good standing shall have the right to continue as a licensee under
the relevant rights granted to it hereunder after agreeing in writing to directly assume all relevant obligations of LICENSEE hereunder. 

17.  RIGHTS AND OBLIGATIONS FOLLOWING TERMINATION  

    17.1.  Termination
of this Agreement, by expiration or otherwise for any reason, shall be without prejudice to: 

	•
	the
rights and obligations provided for in Paragraph 7.3;

	•
	ASU's
right to receive all payments and royalties due and accrued and unpaid on the effective date of the termination;

	•
	the
rights and obligations provided for in Article 10, Article 17 and Article 28; and

	•
	any
other remedies which either party may have under law or equity. 

    17.2.  Following
any termination but not the expiration of this Agreement, LICENSEE and its SUB-LICENSEES, may sell, in accordance with the
terms of this Agreement, any affected LICENSED PRODUCT which was in process of manufacture or finished on the effective date of the termination, but, with respect to these sales, LICENSEE shall
continue to be bound by all of its obligations under this Agreement, including the obligation to render quarterly reports covering sales in accordance with the provisions of Article 9 and the
obligation to pay royalties at the rates set forth in Article 5. The right of each party, subsequent to the loss of its license or
sub-license upon termination of this Agreement, to challenge the validity or alleged infringement under which a license or sub-license is granted, shall not be prejudiced by
reason of the prior existence of this Agreement. 

18.  INSURANCE AND INDEMNIFICATION  

    18.1.  LICENSEE
shall at all times comply, through insurance or self-insurance, with all statutory worker's compensation and employers'
liability requirements covering all employees with respect to activities performed under this Agreement. In addition, LICENSEE shall maintain, from the initiation of human trials, if applicable, and
for so long as LICENSEE customarily maintains insurance for its other products, Comprehensive General Liability Insurance, including Products Liability Insurance, with reputable and financially secure
insurance carriers to cover the activities of LICENSEE and its SUB-LICENSEES. This insurance shall provide minimum limits of liability of $[*] and shall include the
State of Arizona, the Arizona Board of Regents, Arizona State University and their Regents, officers, employers, students and agents as additional insureds. This insurance shall be written to cover
claims made during or after the expiration of this Agreement. At ASU's request, LICENSEE shall furnish a Certificate of Insurance evidencing primary coverage and requiring 30 days prior written
notice of cancellation or material change to ASU. LICENSEE shall advise ASU, in writing, that it maintains excess liability coverage over primary insurance for at least the minimum limits set forth
above. All insurance of LICENSEE shall be primary coverage; insurance of ASU or the State of Arizona shall be excess and noncontributory. 

    18.2.  LICENSEE
agrees to indemnify, hold harmless and defend the State of Arizona, the Arizona Board of Regents, ASU, its officers, employees and
agents; the sponsors of the research that led to the TECHNOLOGY; and the INVENTOR of the patents and patent application included in ASU's COLLECTIVE PATENT RIGHTS (collectively, the INDEMNITEES)
against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from or arising out of exercise of rights granted under this Agreement; provided, however, that LICENSEE shall
have no obligation to indemnify any INDEMNITEE for negligence or willful misconduct or breach of any representation contained in this Agreement by such INDEMNITEE. 

13

    18.3.  ASU shall promptly notify LICENSEE in writing of any claim or suit brought against ASU in respect of which ASU intends to invoke the provisions
of Paragraph 18.2. LICENSEE will keep ASU informed on a current basis of its defense of any claims pursuant to Paragraph 18.2. 

19.  FORCE MAJEURE  

    The parties shall not be liable for failure or delay upon fulfillment of all or part of this Agreement, directly or indirectly owing to acts of Nature,
Governmental orders or restriction, war, warlike condition, revolution, riot, looting, strike, lockout, fire, flood, or any other cause or circumstances beyond the parties' control including the
disability or death of an INVENTOR. 

20.  LATE PAYMENTS  

    In the event royalty payments, re-billings or fees are not received by ASU when due, the LICENSEE shall pay to ASU interest charges at a rate of
ten (10) percent per annum. Interest shall be calculated from the date payment was due until actually received by ASU. 

21.  WAIVER  

    No waiver by either party to this Agreement of any breach or default of any of the covenants or agreements set forth in this Agreement shall be deemed a waiver
as to any subsequent and/or similar breach or default. 

22.  COMPLIANCE  

    LICENSEE shall manufacture LICENSED PRODUCTS in accordance with applicable US law. 

23.  GOVERNING LAWS INCLUDING ARIZONA PUBLIC RECORDS LAW  

    THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF ARIZONA, but the scope and validity of any patent or patent
application shall be governed by the applicable laws of the country of such patent or patent application. 

24.  REPRESENTATIONS  

    Each party represents that it is authorized to enter into this Agreement and that in the due performance of its obligations it would not be acting in violation
of any outstanding obligation, contractual or otherwise, that may be owed by that party to any third party. 

25.  PREFERENCE FOR UNITED STATES INDUSTRY  

    Because this Agreement grants the exclusive right to use or sell the TECHNOLOGY in the United States, the LICENSEE agrees that any products embodying this
TECHNOLOGY or produced through the use of the TECHNOLOGY will be manufactured substantially in the United States. 

26.  FOREIGN GOVERNMENT APPROVAL OR REGISTRATION  

    If the law of any nation requires that this Agreement or any associated transaction be either approved or registered with any governmental agency, the LICENSEE
shall assume all legal obligations to do so. 

27.  EXPORT CONTROL LAWS  

    The LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of LICENSED PRODUCTS and related technical data to
foreign countries, including, without 

14

limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 

28.  MISCELLANEOUS  

    28.1.  This
Agreement will not be binding upon the parties until it has been signed below on behalf of each party; it shall then be effective as of the
EFFECTIVE DATE. No amendment or modification shall be valid or binding upon the parties unless made in writing and signed by each party. 

    28.2.  This
Agreement embodies the entire understanding of the parties and shall supersede all previous communications, representations, or
undertakings, whether verbal or written, between the parties hereto relating to its subject matter. 

    28.3.  LICENSEE
shall have no right to use the name or other designation of the Arizona Board of Regents or Arizona State University or the INVENTOR in
connection with any sale or promotion of LICENSED PRODUCT without the express written consent of the Arizona Board of Regents, ASU or the INVENTOR, respectively. 

    28.4.  If
any provision of this Agreement shall be held to be invalid, illegal, or unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired. 

    28.5.  The
headings of the articles are inserted for convenience of reference only, and are not intended to influence the interpretation of this
Agreement. 

    28.6.  ASU
is a public institution and only those obligations imposed upon ASU which can be lawfully undertaken by the Board of Regents in accordance
with its legislative charter shall be enforceable. 

    28.7.  LICENSEE
agrees that the personnel of LICENSEE will not for any purpose be considered employees or agents of ASU and that LICENSEE assumes full
responsibility for the actions of its personnel while performing services under this Agreement, and shall be solely responsible for their supervision, daily direction and control, payment of salary
(including withholding income taxes and social security), worker's compensation and disability benefits. ASU agrees that the personnel of ASU will not for any purpose be considered employees or agents
of LICENSEE and that ASU assumes full
responsibility for the actions of its personnel while performing services under this Agreement, and shall be solely responsible for their supervision, daily direction and control, payment of salary
(including withholding income taxes and social security), worker's compensation and disability benefits. 

    28.8.  The
parties agree to comply with all applicable state and federal laws, rules, regulations and executive orders as to equal employment
opportunity, nondiscrimination and affirmative action. 

    28.9.  This
Agreement is subject to Section 38-5 11, Arizona Revised Statutes. 

    28.10.  In
the event of a dispute under this Agreement, the parties agree to use arbitration to the extent required under Sections 12-1518
and 12-133, Arizona Revised Statutes. 

    28.11.  To
the extent required by Section 35-214, Arizona Revised Statutes, LICENSEE agrees to retain all books, accounts, reports,
files and other records of LICENSEE relating to this Agreement and make those records available at all reasonable times for inspection and audit by ASU or the Auditor General of the State of Arizona,
or their agents, during the terms of and for a period of five (5) years after the completion of this Agreement. 

15

    IN WITNESS WHEREOF, both ASU and LICENSEE have executed this Agreement, in duplicate originals, by their respective officers hereunto duly authorized, as of the EFFECTIVE DATE. 

	ARIZONA BOARD OF REGENTS a body corporate of the State of Arizona acting for ARIZONA STATE UNIVERSITY ("ASU")	 	SEATTLE GENETICS, INC. ("LICENSEE")
	 
 By:	 
 	 

/s/ ALAN M. POSKANZER   	 
 	 

By:	 
 	 

/s/ H. PERRY FELL   
	 	 	
	 	 	 	

	Name:	 	Alan M. Poskanzer, Ph.D.	 	Name:	 	H. Perry Fell, Ph.D., M.B.A.
	Title:	 	Director

Office of Technology Collaborations & Licensing	 	Title:	 	President & CEO
	 

Date:	 
 	 

February 4, 2000	 
 	 

Date:	 
 	 

2/3/2000
	 	 	
	 	 	 	

16

QuickLinks

LICENSE AGREEMENT No. 651-O1.LIC

AGREEMENTPrepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit 10.20

Confidential treatment requested  

  
      CONTRACT MANUFACTURING AGREEMENT         

    This CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is entered into as of October 16, 2000 (the "Effective Date"), by and between ICOS Corporation
("ICOS"), a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 22021 20th Avenue SE, Bothell, WA 98021 USA and Seattle
Genetics, Inc. ("SGI"), a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 22215 26th Avenue S.E., Suite 3000, Bothell,
WA 98021. 

RECITALS  

    WHEREAS, ICOS is in the business of manufacturing and testing pharmaceutical products; and 

    WHEREAS,
SGI is the proprietor of a certain cDNA known as SGN 30 [*], encoding monoclonal antibodies also known as SGN 30 [*]; and 

    WHEREAS,
ICOS has expertise in the development, evaluation and production of monoclonal antibodies for therapeutic use using cell lines; and 

    WHEREAS,
subject to the terms and conditions set forth in this Agreement, SGI wishes to have ICOS manufacture for SGI a pre-commercial pharmaceutical Product (hereinafter
defined); and 

    WHEREAS,
subject to the terms and conditions set forth in this Agreement, ICOS wishes to manufacture Product for SGI. 

    NOW,
THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

1.  Definitions  

    For purposes of this Agreement, the following terms will have the meanings set forth below: 

    1.1 "Affiliates" means, with respect to any Person, another Person that, directly or indirectly, controls, is controlled
by or is under common control with such Person. The term "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a
Person, whether through the ownership of voting securities, by contract or otherwise. The direct or indirect ownership of at least [*] percent ([*]%)
or, if smaller, the maximum allowed by applicable law, of the voting securities of a business entity or of an interest in the assets, profits or earnings of a Person shall be deemed to constitute
"control" of the Person. 

    1.2 "Applicable Laws" means all applicable ordinances, rules and regulations of any kind whatsoever of any governmental
or regulatory authority, including, without limitation, the FDCA. 

    1.3 "Audit" means a review by SGI or their appointed representatives (such representatives to be reasonably acceptable
to ICOS) of applicable processes, procedures and documents. 

    1.4 "Calendar Quarter" means the three-month period ending on March 31, June 30, September 30 or
December 31. The initial Calendar Quarter will be deemed to begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 or
December 31 of such same year. 

    1.5 "Calendar Year" means the twelve (12) month period ending on December 31. The initial Calendar Year
will be deemed to begin on the Effective Date and end on December 31 of such same year. 

[*]   Confidential treatment requested 

1

    1.6 "Cell Line" means a [*] cell line known as [*], which has been
transfected with a [*] containing certain SGI Materials as described in Appendix B, and will be used to provide the Services herein. Any cell bank provided containing
the transfected cell line will be always subject to the license granted under Appendix G herein. 

    1.7 "cGMP" means Good Manufacturing Practices and General Biologics Products Standards as promulgated under the US
Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610). 

    1.8 "Damages" means any and all reasonable costs, losses, claims, actions, liabilities, fines, penalties, costs and
expenses, court costs, and reasonable fees and disbursements of counsel, consultants and expert witnesses incurred by a party hereto (including interest which may be imposed in connection therewith). 

    1.9 "FDA" means the United States Food and Drug Administration, any comparable agency in any Foreign Jurisdiction, and
any successor agency or entity to any of the foregoing that may be established hereafter. 

    1.10 "FDCA" means the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et
seq.). 

    1.11 "FOB" means ICOS has fulfilled its obligation to deliver when it has made the object of delivery available at its
premises to SGI or SGI's agent (or to SGI's carrier). For the avoidance of doubt, unless otherwise agreed in writing, ICOS is not responsible for loading the object of delivery on to the vehicle
provided by SGI or SGI's agent (or to ICOS's nominated carrier) or for delaying the object of delivery for export. 

    1.12 "Foreign Jurisdiction" means any jurisdiction where Product will be used by SGI, not governed by the United States
or any political subdivision thereof. 

    1.13 "ICOS Know-How" means unpatented and/or unpatentable technical information, including ideas, concepts,
inventions, discoveries, data, designs, formulas, specifications, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification
techniques, and assay protocols owned by ICOS as of the Effective Date which may be necessary for the practice of the ICOS-Patent Rights and which ICOS has the right to license. ICOS
Know-How shall not include the ICOS-Patent Rights. All ICOS Know-How shall be Confidential Information of ICOS. 

    1.14 "ICOS Patent Rights" mean the patent applications and patents listed on Exhibit A to Appendix G
hereto and all divisions, continuations, continuations-in-part, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; and all
U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues, and re-examinations. 

    1.15 "Manufacturing Specifications" means the specifications for manufacturing the Product. Prior to the initiation of
the first cGMP manufacturing run an Appendix C-1 signed by both parties setting forth the initial Manufacturing Specifications shall be appended to this Agreement and shall contain
at a minimum a collection of documents containing certain specifications, procedures, assay methods (QC Release Tests), personnel contacts and any other information as may be needed and agreed by the
parties relating to the manufacture of Product by ICOS for SGI. This Appendix C-1 shall also contain a statement to be agreed and acknowledged by ICOS and SGI that SGI adopts the
initial Manufacturing Specifications as its own specification in conformance with Clause 6.7 herein. Any changes or additions to the Manufacturing Specifications shall be made with the written
approval of SGI. 

    1.16 "NDA" means New Drug Application or any comparable application required by a Foreign Jurisdiction filed for the
Product by SGI with the FDA and all subsequent submissions, supplements or amendments related thereto. 

2

    1.17 "Person" means a natural person, a corporation, a partnership, a trust, a joint venture, a limited liability
company, any governmental authority or any other entity or organization. 

    1.18 "Price" means the price specified in Appendix E for the Services. 

    1.19 "Process" means the process for the production of the Product from the Cell Line using the Manufacturing
Specifications, including any improvements thereto from time to time made as a result of the Services. 

    1.20 "Product" means a monoclonal antibody derived from the Cell Line, manufactured by a process utilizing the
Manufacturing Specifications, and incorporating technology licensed from ICOS in Appendix G. 

    1.21 "Product Specifications" means the product specifications as described in Appendix C. 

    1.22 "Services" means all or any part of the services the subject of this Agreement or Proposal (including, without
limitation, cell culture evaluation, purification evaluation, master, working and extended cell bank creation, and sample and bulk production), particulars of which are set out in Appendix A. 

    1.23 "SGI-Patent Rights" means all patents and patent applications of any kind throughout the world relating
to the Process which from time to time SGI is the owner of or is entitled to use. 

    1.24 "SGI Information" means all confidential, technical and other information not known to ICOS and/or not in the
public domain relating to the Cell Line, the Process and the Product, from time to time supplied by SGI to ICOS, or arranged by SGI to be supplied by a third party (such as a prior manufacturer) to
ICOS. 

    1.25 "SGI Know-How" means all technical and other information relating to the Process known to SGI from time
to time other than confidential SGI Information and information in the public domain. 

    1.26 "SGI Materials" means the Materials supplied by SGI to ICOS (if any) and identified as such by Appendix B
hereto. 

    1.27 "SGI Technology" means all of SGI's patents, technology, know-how and proprietary information necessary
to manufacture the Product. 

    1.28 "SGI Tests" means the tests to be carried out on the Product immediately following receipt of the Product by SGI,
particulars of which are set out in Appendix C. 

    1.29 "Special Term" means any term additional or supplemental to this Agreement from time to time agreed to in writing
between ICOS and SGI. Particulars of any Special Terms are set out in Appendix F. 

    1.30 "Terms of Payment" means the terms of payment specified in Appendix E. 

    1.31 "Testing Laboratories" means any third party instructed by ICOS to carry out tests on the Cell Line or the Product. 

    1.32 "United States" means the fifty (50) states, the District of Columbia and all of the territories of the
United States of America. 

2.  Supply by SGI  

    2.1 Prior
to or immediately following the Effective Date of the Agreement SGI shall supply to ICOS, SGI Information, together with full details of any hazards relating
to SGI Materials, their storage and use. On review of this SGI Information, SGI Materials shall be provided to ICOS at ICOS's request when ICOS has satisfactorily determined that SGI Materials do not
pose a hazard to ICOS. SGI shall assist ICOS in making such determination, but in no way be responsible for deciding 

3

the safety of the SGI Materials to ICOS's facilities. All property rights in the SGI Information, SGI Technology and/or SGI Materials supplied to ICOS shall remain vested in SGI. 

    2.2 SGI
hereby grants ICOS the non-exclusive right to use the SGI Materials, SGI Information, SGI Know-how and SGI Technology for the sole
purpose of providing the Services. ICOS hereby undertakes not to use SGI Materials, SGI Information, SGI Know-how or SGI Technology (or any part thereof) for any other purpose. 

    2.3 ICOS
shall: 

    2.3.1  at
all times use all reasonable endeavors to keep the SGI Materials secure and safe from loss or damage but in no case in a lesser manner than
ICOS stores its own material of similar nature; 

    2.3.2  not
transfer to a third party any part of the SGI Materials or the Product, except save for the purpose of any tests at the Testing Laboratories,
provided, that, SGI is given prior notification or if SGI has given prior written consent to such transfer; and 

    2.3.3  provide
that such Testing Laboratories are subject to obligations of confidence materially in the form of those obligations of confidence imposed
on ICOS under this Agreement. 

    2.4 SGI
warrants to ICOS that SGI is and shall at all times throughout the duration of the Agreement remain entitled to supply the SGI Materials, SGI Information and
SGI Know-how to ICOS for the performance of the Services. 

    2.5 SGI
warrants that the use by ICOS of SGI Materials, SGI Information and SGI Know-how for the Services will not infringe or is not alleged to infringe
any rights (including, without limitation, any intellectual or other proprietary rights) vested in any third party. 

    2.6 [*]

    2.7 [*]

    2.8 Notwithstanding
the above, ICOS shall be at liberty to use SGI Information as it sees fit in providing the Services subject to nondisclosure pursuant to
Clause 7. 

    2.9 The
obligations of each party under this Clause 2 shall survive the termination of the Agreement for whatever reason. 

3.  Provision of the Services  

    3.1 ICOS
shall diligently perform the Services as provided in Appendix A and shall use all reasonable commercial efforts to achieve the estimated schedules,
specifications and amounts of Product. Furthermore, ICOS shall keep SGI regularly informed of any changes to the estimated schedules for performance of the Services and provide a monthly report, in a
form agreed by the parties. 

    3.2 Due
to the unpredictable nature of the biological processes involved in the Services, the schedules set down for the performance of the Services (including, without
limitation, the dates for production and delivery of Product) set out in Appendix D are estimates only. 

    3.3 In
the event that ICOS is unable to, or notifies SGI, in writing, that it is unable, for any reason, except events of Force Majeure where Section 9.1 of this
Agreement shall be applicable, to supply agreed quantities of Product by [*], SGI may at its discretion, seek to manufacture or have manufactured by a third party designated by
SGI that quantity of the Products required by SGI that ICOS is unable to supply. Provided however, that prior to manufacture of Product by a third party, SGI and ICOS negotiate in good faith the
supply of undelivered Product by ICOS to SGI at a future date agreed upon by the parties. If the parties cannot agree on a time period for delivery of Product and 

4

SGI determines to manufacture or have manufactured by a third party such Products, ICOS will supply SGI and/or any such third party all reasonably available information and data relating to the
Manufacturing Specifications. 

    3.4 Delivery
of bulk Product shall be FOB ICOS's premises. Risk in and title to bulk Product shall pass on delivery. Transportation of bulk Product, whether or not
under any arrangements made by ICOS on behalf of SGI, shall be made at the sole risk and expense of SGI. In the case where SGI accepts ICOS Product tests (QC Release Tests) and shipment is to be made
to a third party, "delivery" for the purposes of risk in and title to bulk Product, shall occur upon the signed acceptance of ICOS Product tests (QC Release Tests) by SGI. Unless otherwise agreed
between the parties in writing, ICOS will tender delivery to SGI upon completion of all QA and QC tests approximately six (6) to eight (8) weeks following completion of manufacture. 

    3.5 Unless
otherwise agreed, ICOS shall package and label Product for FOB delivery in accordance with its standard operating procedures. It shall be the responsibility
of SGI to provide prior written notice to ICOS of any special packaging and labeling requirements for Product. All additional costs and expenses (including reasonable profit) of whatever nature
incurred by ICOS in complying with such special requirements shall be charged to SGI in addition to the Price. 

    3.6 Upon
completion of the Services, or as soon thereafter as can be mutually agreed, ICOS will deliver to SGI a cell bank, generated by ICOS, comprised of the Cell
Line and used to provide the Services herein. 

    3.7 Joint
Communication on Manufacturing: ICOS and SGI shall communicate and cooperate on a regular basis during the provision of Services herein and in the event that
the parties observe the need for a regular and active committee, such body shall be established and meet regularly to discuss and communicate the progress of the Services. 

4.  SGI Tests and Return Procedures  

    4.1 Except
where SGI has accepted ICOS Product tests and provided written notice to ICOS of such acceptance, promptly following delivery of Product, SGI shall carry out
SGI Tests. PROVIDED ALWAYS that the Product Specifications for such Product has been agreed between the parties hereto.
If SGI Tests show that the Product fails to meet Product Specifications, SGI shall give ICOS written notice thereof as soon as practicable but in no case later than [*]
([*]) [*] from the date of FOB delivery of the Product and shall return such Product to ICOS's premises for further testing. In the absence of such
written notice Product shall be deemed to have been accepted by SGI as meeting Product Specifications. If ICOS agrees that Product returned to ICOS fails to meet Product Specifications and that such
failure is not due (in whole or in part) to acts or omissions of SGI or any third party after FOB delivery of such Product, ICOS shall at SGI's discretion replace such Product at its own cost and
expense. ICOS shall be entitled to consider its other obligations and its commercial commitments to third parties in the timing of such replacement. SGI acknowledges that there may, therefore, be a
delay in the timing of the replacement of such Product; provided, however, that such delay shall not exceed [*] from date of return to ICOS. 

    FOR
THE AVOIDANCE OF DOUBT, WHERE THE SPECIFICATION HAS NOT BEEN AGREED BY THE PARTIES HERETO ICOS SHALL BE OBLIGED ONLY TO USE ITS REASONABLE ENDEAVORS TO PRODUCE PRODUCT THAT MEETS
DRAFT PRODUCT SPECIFICATIONS. 

    4.2 If
there is any dispute concerning whether Product returned to ICOS fails to meet Product Specifications or whether such failure is due (in whole or in part) to
acts or omissions of SGI or any third party after FOB delivery of such Product, such dispute shall be referred for decision to an 

5

independent expert (acting as an expert and not as an arbitrator) to be appointed by agreement between ICOS and SGI. 

    The
costs of such independent expert shall be borne by the party initiating the dispute. The decision of such independent expert shall be in writing and, save for obvious and material
error, shall be binding on both ICOS and SGI. 

    4.3 In
the event that the parties hereto agree that a shipment or batch of Product fails to meet Product Specifications, the entire shipment or batch of Product that
failed to meet Product Specifications shall either be returned to ICOS or destroyed, at ICOS's option. 

    4.4 The
provisions of Clauses 4.1 and 4.2 shall be the sole remedies available to SGI in respect of Product that fails to meet Product Specifications. 

5.  Price and Terms of Payment  

    5.1 SGI
shall pay the Price in accordance with the Terms of Payment all as specified in Appendix E. 

    5.2 Unless
otherwise indicated in writing by ICOS, all prices and charges are exclusive of State Sales Tax or of any other applicable taxes, levies, duties and fees of
whatever nature imposed by or under the authority of any government or public authority, which shall be paid by SGI (other than taxes on ICOS's income). All invoices are strictly net and payment must
be made within thirty (30) days of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim of any nature. 

    5.3 In
default of payment on due date interest shall accrue on a day to day basis with effect from the date which is [*]
([*]) [*] after the due date for payment on any amount overdue at the maximum rate allowable under Washington State Law. 

6.  Warranty and Limitation of Liability  

    6.1 ICOS
warrants that: 

    6.1.1  the
Services shall be performed in accordance with Clause 3.1; and 

    6.1.2  the
Product shall meet Product Specifications, except where the Product Specifications has not been agreed between the parties hereto in which
case ICOS shall be obliged only to use its reasonable commercial efforts to produce Product that meets draft Product Specifications. 

    6.1.3  the
Product delivered to SGI pursuant to this Agreement shall conform to the Product Specifications and that such Product shall (i) be
free from defects in material and workmanship, (ii) be manufactured in accordance with cGMP and (iii) be manufactured in accordance with Appendix C hereof. 

    6.2 Clause 6.1
is in lieu of all conditions, warranties and statements in respect of the Services and/or the Product whether expressed or implied by statute,
custom of the trade or otherwise (including but without limitation any such condition, warranty or statement relating to the description or quality of the Product, its fitness for a particular purpose
or use under any conditions whether or not known to ICOS) and any such condition, warranty or statement is hereby excluded. ICOS MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
PRODUCT. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY ICOS. IN NO
EVENT SHALL ICOS BE LIABLE FOR INDIRECT, INCIDENTAL OR COMMERCIAL CONSEQUENTIAL DAMAGES. 

6

    6.3 Without prejudice or modification to the terms of Clauses 6.1 and 6.2 the liability of ICOS to SGI, its permitted assigns and successors in interest, for any loss
suffered by SGI or its permitted assigns and successors in interest, arising as a direct result of a breach of this Agreement, or of any other liability, including without limitation,
misrepresentation and negligence (whether active, passive or imputed), arising out of the Agreement and Services provided thereunder, including without limitation the production and/or supply of the
Product, shall be limited to the payment of damages which shall not exceed in US Dollars THE PRICE FOR SERVICES PAID BY SGI UNDER THE AGREEMENT save in the event and to the extent such damages are
caused by ICOS's willful or intentional breach of this Agreement or willful or intentional misconduct in the performance of the Services. 

    6.4 Subject
to Clause 6.3, ICOS shall not be liable for the following loss or damage howsoever caused (even if foreseeable or in the contemplation of ICOS or
SGI): 

    6.4.1  loss
of profits, business or revenue suffered by SGI or any other person who may be subrogated to, or assigned rights in the loss or damage; or 

    6.4.2  special,
indirect or consequential loss, whether suffered by SGI or any other person. 

    6.5   SGI
shall indemnify and hold harmless and maintain ICOS indemnified and held harmless against all Damages in respect of: 

    6.5.1  any
product liability in respect of Product; and 

    6.5.2  any
negligent (active, passive or imputed), gross negligence or intentional act or omission of SGI in relation to the use, processing, storage or
sale of the Product. 

    6.6   Except
as expressly granted in Appendix G and the right allowed to transfer the manufacturing process in Sections 3.3 and 9.1, no express or
implied license is granted by this Agreement. 

    6.7 SGI
represents and warrants that unless already expressly agreed in a written and executed document immediately prior to the initiation of the first cGMP
manufacturing run, SGI will adopt the initial Manufacturing Specifications as its own specification. Any changes or additions to the Manufacturing Specifications shall be made with the written
approval of SGI. 

    6.8 The
obligations of SGI under this Clause 6 shall survive the termination for whatever reason of the Agreement. 

7.  Confidentiality  

    7.1 SGI
acknowledges that ICOS Know-How, and ICOS acknowledges that SGI Information, SGI Know-How, SGI Materials, or SGI Technology with which
each is supplied by the other pursuant to the Agreement, subject to Clause 7.4, in circumstances imparting an obligation of confidence and each agrees to keep such ICOS Know-How or
such SGI Information, SGI Know-How, SGI Materials, or SGI Technology confidential and to respect the other's proprietary rights therein and not at any time for any reason whatsoever to
disclose or permit such ICOS Know-How or such SGI Information, SGI Know-How, SGI Materials, or SGI Technology to be disclosed to any third party save as expressly
provided herein and not to use such ICOS Know-How or SGI Information, SGI Know-How, SGI Materials, or SGI Technology for any other purpose other than as expressly provided
herein. 

    7.2 SGI
and ICOS shall each ensure that all their respective employees, consultants and contractors having access to confidential ICOS Know-How or
confidential SGI Information, SGI Know-How, SGI Materials, or SGI Technology shall be subject to the same obligations of confidence as the principals pursuant to Clause 7.1 and
shall be subject to written confidentiality agreements in support of such obligations. 

7

    7.3 ICOS and SGI each undertake not to disclose or permit to be disclosed to any third party, or otherwise make use of or permit to be made use of, any trade secrets or
confidential information relating to the technology, business affairs or finances of the other, any subsidiary, holding company or subsidiary or any such holding company of the other, or of any
suppliers, agents, distributors, licensees of the other to which either party comes into possession of under this Agreement, except as specifically stated in Appendix G or agreed between the
parties in writing. 

    7.4 The
obligations of confidence referred to in this Section 7 shall not extend to any information which: 

    7.4.1  is
or becomes generally available to the public otherwise than by reason of a breach by the recipient party of the provisions of this
Section 7; 

    7.4.2  is
lawfully known to the recipient party prior to its receipt from the other; 

    7.4.3  is
subsequently disclosed to the recipient party without being made subject to an obligation of confidence by a third party that does not have a
prior obligation of confidence to SGI or ICOS, as the case may be; or 

    7.4.4  which
may be required to be disclosed under any statutory, regulatory or similar legislative requirement, subject to the imposition of
obligations of confidentiality to the extent allowed and provided further that each party shall, unless prohibited by law, use reasonable efforts to notify the
other party of such compelled disclosure prior to such disclosure in order to seek injunctive or any other relief provided in law or equity. 

    7.5 SGI
acknowledges that: 

    7.5.1  ICOS
Know-How is vested in ICOS; and 

    7.5.2  SGI
shall not at any time have any right, title, license or interest in or to ICOS Know-How or any other intellectual property rights
relating to the Process which are vested in ICOS or to which ICOS is otherwise entitled, except as specifically provided in Appendix G. 

    7.6 ICOS
acknowledges that: 

    7.6.1  SGI
Information, SGI Materials, SGI Technology, SGI Know-How and SGI-Patent Rights are vested in SGI; and 

    7.6.2  save
as provided herein ICOS shall not at any time have any right, title, license or interest in or to SGI Information or any other intellectual
property rights vested in SGI or to which SGI is entitled. 

    7.7 The
obligations of ICOS and SGI under this Section 7 shall survive the termination of the Agreement for whatever reason. 

8.  Termination  

    8.1 If
it becomes apparent to either ICOS or SGI at any stage in the provision of the Services that it will not be possible to complete the Services for scientific or
technical reasons, a [*] ([*]) [*] period shall be allowed for discussion to resolve such problems. 

    If
such problems are not resolved at the end of such [*] ([*]) [*] period, ICOS and SGI shall each have the
right to terminate the Agreement. In the event of such termination, SGI shall pay to ICOS a termination sum calculated by reference to all the Services performed by ICOS prior to such termination
(including a pro rata proportion (as demonstrated by signed timesheets in so far as they are applicable) of the Price for any stage of the Services which is in process at the date of termination) and
all expenses reasonably incurred by ICOS in giving effect to such termination, including the costs of terminating any commitments entered into under the Agreement, such termination sum not to 

8

exceed the Price. Provided however, that if the termination sum is less than the amount of any advance payments made by SGI against the performance of the Services a payment in sum equal to the
residue of such advance payments shall be made to SGI. 

    8.2 SGI
shall be entitled to terminate this Agreement at any time for any reason by [*] ([*])
[*] notice to ICOS in writing providing that any termination or cancellation agreed between the parties hereto has been paid. 

    In
the event of SGI serving written notice to terminate this Agreement which notice is expressly to be given pursuant to this Clause 8.2, SGI shall: 

    8.2.1  pay
ICOS a termination sum calculated by reference to all the Services performed by ICOS prior to such termination (including a pro rata
proportion (as demonstrated by signed timesheets in so far as they are applicable) of the Price for any stage of the Services which is in process at the date of termination) and all expenses
reasonably incurred by ICOS in giving effect to such termination, including the costs of terminating any commitments entered into under the Agreement such termination sum not to exceed the Price plus
any changes. Provided however, that if the termination sum is [*] a payment in sum equal to the [*] shall be made to SGI; and 

    8.2.2  In
the event notice to terminate this Agreement pursuant to this Clause 8.2 is issued to ICOS later than [*], SGI
shall pay ICOS a sum equal to the [*], in question which payment shall fall due to ICOS on or before the date of termination of the Services. 

    8.3 ICOS
and SGI may each terminate the Agreement forthwith by notice in writing to the other upon the occurrence of any of the following events: 

    8.3.1  if
the other commits a breach of the Agreement which (in the case of a breach capable of remedy) is not remedied within
[*] ([*]) [*] of the receipt by the other of written notice identifying the breach with specificity and requiring its remedy; or 

    8.3.2  if
the other ceases for any reason to carry on business or convenes a meeting of its creditors or has a receiver or manager appointed in respect
of all or any part of its assets or is the subject of an application for an administration order or of any proposal for a voluntary arrangement or enters into liquidation (whether compulsorily or
voluntarily) or undergoes any analogous act or proceedings under foreign law; provided, however, either party may merge with or into another equity pursuant to which the obligations of this Agreement
will be assumed or effect the sale of all its assets or substantially all of its assets pursuant to which the acquiring party will assume such party's obligations under this Agreement without notice
to or waiver by the other party. 

    8.4 Upon
the termination of the Agreement for whatever reason: 

    8.4.1  ICOS
shall promptly return all SGI Information to SGI and shall dispose of or return to SGI, SGI Materials and any materials therefrom, as
directed by SGI; 

    8.4.2  SGI
shall promptly return to ICOS all ICOS Know-How it has received from ICOS; 

    8.4.3  SGI
shall not thereafter use or exploit the ICOS Know-How in any way whatsoever for production by SGI, or production by a
third-party. If SGI determines to manufacture or have manufactured by a third party such Products, ICOS will give SGI and/or any such Third Party all reasonably necessary information and cooperation
to enable SGI or such third party to manufacture the Products in connection with the Manufacturing Specifications. 

    8.4.4  save
to the extent expressly stated elsewhere in this Agreement, ICOS may thereafter use or exploit the ICOS Know-How in any way
whatsoever without restriction; and 

9

    8.4.5  ICOS and SGI shall do all such acts and things and shall sign and execute all such deeds and documents as the other may reasonably require to
evidence compliance with this Clause 8.4. 

    8.5 Termination
of the Agreement for whatever reason shall not affect the accrued rights of either ICOS or SGI arising under or out of this Agreement and Clauses 2, 6,
7, and 8 and any definitions in Clause 1 required to interpret such surviving provisions, and all provisions which are expressly to survive the Agreement or have a continuing obligation shall
remain in full force and effect. Further, Appendix G shall survive termination of this Agreement and shall exist as a complete and separate agreement. 

9.  Force Majeure  

    9.1 Neither
ICOS nor SGI shall be deemed to be in default nor be liable for loss, damage, or delay in performance, when and to the extent due to causes beyond its
reasonable control or from fire, strike, labor difficulties, insurrection or riot, embargo, or inability to obtain materials from usual sources, or any other unforeseeable cause or causes beyond the
reasonable control and without the fault or negligence of the party so affected, or from defects or delays in the performance of its suppliers or subcontractors due to any of the foregoing enumerated
causes. If ICOS is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and shall give written notice thereof to SGI specifying the matters
constituting Force Majeure together with such evidence as ICOS reasonably can give and specifying the period for which it is estimated that such prevention or delay will continue, ICOS shall be
excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue, provided
that within [*] ([*]) days from the date of such notice, ICOS shall provide SGI with written notice of the anticipated date of resumption of
performance. In the event that the anticipated date of such resumption is greater than [*] ([*]) months from the date of the original notice, SGI may
invoke the remedy of third party manufacture provided in Section 3.3 herein or terminate this Agreement. 

10.  Governing Law, Jurisdiction and Enforceability  

    10.1   This
Agreement shall be governed and interpreted, and all rights and obligations of the parties shall be determined, in accordance with the laws
of the State of Washington and the United States of America without regards to principles of conflicts of law. 

    10.2   No
failure or delay on the part of either ICOS or SGI to exercise or enforce any rights conferred on it by the Agreement shall be construed or
operate as a waiver thereof nor shall any single or partial exercise of any right, power or privilege or further exercise thereof operate so as to bar the exercise or enforcement thereof at any time
or times thereafter of any other right. 

    10.3   The
illegality or invalidity of any provision (or any part thereof) of the Agreement shall not affect the legality, validity or enforceability of
the remainder of its provisions or the other parts of such provision as the case may be and the Agreement shall continue in full force and effect without such provision. 

11.  Miscellaneous  

    11.1   Neither
party shall be entitled to assign, or in any way transfer the benefit and/or the duties of this Agreement without the prior written
consent of the other which consent shall not be unreasonably withheld or delayed, except that either party shall be entitled without the prior written consent of the other to assign, transfer, charge,
subcontract, deal with or in any other manner make over the benefit and/or burden of this Agreement to an Affiliate, or to any limited liability partner or to any [*] company
of which the party in question is the beneficial owner of [*] percent ([*]%) of the 

10

issued share capital thereof or to any company with which the party in question may merge or to any company to which that party may transfer its assets and undertakings. 

    11.2   The
text of any press release or other communication to be published by or in the media concerning the subject matter of the Agreement shall
require the prior written approval of ICOS and SGI. 

    11.3  Notices.  All notices, requests, demands, waivers, consents, approval or other communications to
any party hereunder shall be in writing and shall be deemed to have been duly given if delivered personally to such party or sent to such party by recorded electronic transmission (facsimile) or by
registered or certified mail, postage prepaid, to its address as shown below: 

    SGI:      Seattle
Genetics, Inc.

22215 26th Avenue S.E., Suite 3000

Bothell, WA 98021

Attention: H. Perry Fell 

    ICOS:     ICOS
Corporation

22021 20th Avenue S.E.

Bothell, WA 98021

Attention: Legal Department 

or
to such other address as the addressee may have specified in a notice duly given to the sender as provided herein. Such notice, request, demand, waiver, consent, approval or other communications
will be deemed to have been given as of the date so delivered, telegraphed, telexed, or five (5) days after so mailed. 

    11.4  Independent Contractor.  Each party shall be and shall endeavor to act as the independent
contractor of the other party. Neither party shall be the legal agent of the other for any purpose whatsoever and therefore has no right or authority to make or underwrite any promise, warranty or
representation, to execute any contract or otherwise to assume any obligation or responsibility in the name of or on behalf of the other party, except to the extent specifically authorized in writing
by the other party. Neither of the parties hereto shall be bound by or liable to any third persons for any act or for any obligation or debt incurred by the other toward such third party, except to
the extent specifically agreed to in writing by the party so to be bound. 

    11.5  Headings.  All section headings and numbering contained in this Agreement are for convenience of
reference only, do not form a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. 

    11.6  Entire Agreement.  The Agreement embodies the entire understanding of ICOS and SGI and there are no
promises, terms, conditions or obligations, oral or written, expressed on implied, other than those contained in the Agreement. The terms of the Agreement shall supersede all previous agreements (if
any) which may exist or have existed between ICOS and SGI relating to the Services. 

    12.  Other Terms.  The parties agree to such other product specific terms and conditions as set forth in
Appendix F. 

11

    IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written. 

	ICOS CORPORATION	 	SEATTLE GENETICS, INC.
	 

By:	 
 	 

/s/ GARY WILCOX   
 Name: Gary Wilcox

Title: EVP, Operations	 
 	 

By:	 
 	 

/s/ H. PERRY FELL   
 Name: H. Perry Fell

Title: C.E.O.

12

 

  APPENDIX E
  Price and Payment Terms         

	Stage
 
	 	Terms
	 	Estimated Date

of Payment
	 	Total Price

for Stage

	Cell Line & Process Development	 	$[*] upon signing of the agreement1; $[*] if decision is made to continue development following titer determinations from CHO cells;	 	[*]

[*]	 	$[*]
	 	 	$[*] upon decision to move forward with process development for either SGN 30 $[*];	 	[*]	 	 
	 	 	$[*] at completion of Cell Line & Process Development stage as described in Appendix A, Section 2	 	[*]	 	 
	 

Serum-free Cell Line Development	 
 	 

$[*] at stage initiation;	 
 	 

[*]	 
 	 

$[*]
	 

 	 
 	 
 Incentive payments:

Based on baseline titer of [*], $[*] for each titer improvement of [*] above baseline up to [*]. (Maximum incentive payment of $[*])	 
 	 

 	 
 	 

 
	 

 	 
 	 

[*]% due upon delivery of process and cell-line to SGI or Third Party manufacturer;	 
 	 

[*]	 
 	 

 
	 

 	 
 	 

[*]% due upon first entry in man of resulting product.	 
 	 

[*]	 
 	 

 
	 

Manufacturing (Including Transfer and Scale-Up; Development run and Production runs)2,3	 
 	 

$[*] at initiation of Process Transfer to Manufacturing and Scale-up stage as described in Appendix A, Section 3.1.1;	 
 	 

[*]	 
 	 

$[*]
	 

 	 
 	 

[*]% of balance at initiation of Development run4;	 
 	 
 [*]	 
 	 

 
	 	 	[*]% of balance at [*] GMP Production run #1;	 	[*]	 	 
	 	 	[*]% of balance at [*] GMP Production run #2;	 	[*]	 	 
	 	 	[*]% of balance at Lot Release.	 	[*]	 	 

1 Includes
$[*] non-refundable payment made on [*]. 

2 Seattle
Genetics will bear the cost of the resins needed for the process to an agreed upon amount. 

3 ICOS
will deliver [*] gm of cGMP antibody and suitable documentation to support regulatory filings. If ICOS produces additional cGMP antibody,
Seattle Genetics can purchase additional amounts greater than [*] gm at the rate of $[*]/gm. 

4 Initiation
of Development run is defined as inoculation of cell line into seed-train bioreactors. 

[*]   Confidential
treatment requested 

  APPENDIX G
  NON-EXCLUSIVE LICENSE AGREEMENT         

    This Non-exclusive License Agreement (the "Agreement"), effective as of October 16th, 2000 (The "Effective Date"), is entered
into by and between ICOS Corporation, a Delaware corporation having offices at 22021 20th Avenue SE, Bothell, WA 98021, U.S.A., ("ICOS"), and Seattle
Genetics, Inc., a Delaware corporation having offices at 22215 26th Avenue S.E., Suite 300, Bothell, WA 98021 ("LICENSEE"). All references to
LICENSEE in this Agreement shall include its Affiliates (as such term is defined below). 

  BACKGROUND         

    A.  ICOS
is the owner of certain Patent Rights (as defined below) and LICENSEE wishes to acquire a non-exclusive license under the Patent Rights for use in
the Field; and 

    B.  ICOS
is willing to grant LICENSEE such a non-exclusive license, on the terms and conditions set forth below. 

    NOW,
THEREFORE, in consideration of the promises and the mutual covenants hereinafter recited, the parties agree as follows: 

  ARTICLE 1—DEFINITIONS         

    In this Agreement, the following terms shall have the meanings set forth in this Article. 

    1.1 "Affiliate" means any corporation or other entity which is directly or indirectly controlling, controlled by or
under common control with a party hereto. For the purpose of this Agreement, "control" shall mean the direct or indirect ownership of at least [*] percent
([*]%) of the outstanding shares or other voting rights of the subject entity to elect directors. 

    1.2 "BLA" means a Biologics License Application, as defined in the U.S. Food, Drug and Cosmetic Act and the regulations
promulgated thereunder and any corresponding U.S. or foreign application, registration or certification. 

    1.3 "Change in Control" shall mean (i) the merger or consolidation of LICENSEE with another entity where less
than [*] percent ([*]%) of the outstanding voting securities of the combined entity immediately after such merger or consolidation is held by the
holders of the outstanding voting securities of LICENSEE immediately prior to such merger or consolidation; (ii) the acquisition by means of a stock purchase, directly or indirectly, by a party
or parties acting in concert of [*] percent ([*]%) or more of LICENSEE's voting stock in a single transaction or a series of related transactions; but
excluding any transaction that is primarily for financing purposes or, (iii) the sale of all or substantially all of the assets of LICENSEE. 

    1.4 "Confidential Information" shall mean (i) any proprietary or confidential information or material in tangible
form disclosed hereunder that is designated as "Confidential" at the time it is delivered to the receiving party, or (ii) proprietary or confidential information disclosed orally hereunder
which is identified as confidential or proprietary when disclosed and such disclosure of confidential information is confirmed in writing within thirty (30) days by the disclosing party. 

    1.5 "Field" means (i) production of recombinant proteins for the development, manufacture, use and sale of
products for human therapeutic uses, and (ii) for internal research purposes. For the purposes of this Agreement, "internal research purposes" shall mean any activity by SGI for its own
research and shall not include any right of transfer to a third party and shall not include any product which shall become a Licensed Product upon which royalties are due. 

1

    1.6 "IND" shall mean an Investigational New Drug application, as defined in the U.S. Food, Drug and Cosmetic Act and the
regulations promulgated thereunder for initiating clinical trials in the United States, or any corresponding foreign application, registration or certification. 

    1.7 "Licensed Product" shall mean any product in development by LICENSEE whose development, manufacture, use or sale
would constitute an infringement of a Valid Claim. in the country of development, manufacture, use or sale. 

    1.8 "Licensed Technology" means the Patent Rights. 

    1.9 "Net Sale" shall mean revenues on an accrual basis, in accordance with U.S. generally accepted accounting
principles, as follows: the invoice price of Licensed Products sold by LICENSEE its affiliates or its sublicensees to third parties, less to the extent included in such invoice price the total of:
(1) ordinary and customary trade discounts actually allowed; (2) credits, rebates and returns (including, but not limited to, wholesaler and retailer returns); (3) freight,
postage, insurance and duties paid for and separately identified on the invoice or other documentation maintained in the ordinary course of business, and (4) excise or value-added taxes, other
consumption taxes, customs duties and compulsory payments to governmental authorities actually paid and separately identified on the invoice or other documentation maintained in the ordinary course of
business. Net Sales shall also include the fair market value of all other consideration received by LICENSEE in respect of Licensed Products, whether such consideration is in cash, payment in kind,
exchange or another form. 

    1.10 "Patent Rights" shall mean the patent applications and patents listed on Exhibit A hereto and all divisions,
continuations, continuations-in-part, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; and all U.S. and foreign patents
issuing on any of the preceding applications, including extensions, reissues, and reexaminations. 

    1.11 "Phase II" or "Phase III" shall mean a Phase II or, as the case may be, Phase III clinical trial as prescribed by
applicable FDA regulations, or corresponding regulations of any comparable entity. 

    1.12 "Valid Claim" means (i) a claim of an issued and unexpired patent included within the Patent Rights which
has not been held invalid in a final decision of a court of competent jurisdiction from which no appeal may be taken, and which has not been disclaimed or admitted to be invalid or unenforceable
through reissue or otherwise, or (ii) a claim of a pending patent application within the Patent Rights. 

  ARTICLE 2—LICENSE         

    2.1.1  Grant of License.  ICOS hereby grants to LICENSEE and LICENSEE hereby accepts from ICOS, upon and
subject to the terms and conditions herein specified, a worldwide, non-exclusive, royalty-bearing license under the Patent Rights to make, to have made, to use and to sell Licensed
Products in the Field. LICENSEE shall have the right to sublicense its foregoing license rights to the Patent Rights for the purposes of developing, manufacturing, marketing or selling Licensed
Products, the development of which was commenced by LICENSEE (and not the sublicensee) prior to entering into such sublicense. The sublicense rights here granted are limited to sublicenses undertaken
for LICENSEE to engage in its own core business and are not granted nor shall be used to materially compete with ICOS licensing of the Patent Rights herein. LICENSEE shall not use the Patent Rights
outside the field. 

    2.1.2  Grant Back to Licensor.  In the event that LICENSEE modifies the [*]
described by the Patent Rights beyond "the use" expressly allowed and licensed herein to practice the Patent Rights within the Field, Licensee agrees to grant, and hereby does grant to ICOS, an
exclusive, worldwide, fully paid up license to any and all intellectual property and know-how arising out of the LICENSEE's use outside the permitted scope of the License granted in 2.1.1
above. 

2

    2.2  No Implied Rights.  Only the license granted pursuant to the express terms of this Agreement shall
be of any legal force or effect and no rights to transfer or, except as set forth in Section 2.1, sublicense the licensed rights are granted herein. No other license rights shall be granted or
created by implication, estoppel or otherwise. 

    2.3  Ownership: Enforcement.  At all times ICOS will retain ownership of the Licensed Technology and may
use, license and commercialize such Licensed Technology itself or with third parties. ICOS retains the right, at its sole discretion, to enforce, maintain and otherwise protect the Licensed
Technology. LICENSEE shall give ICOS immediate notice of any infringement by a third party of any of the Patent Rights which comes to LICENSEE'S attention during the term of this Agreement. LICENSEE
will cooperate with ICOS with respect to any actions ICOS may choose to take pursuant to this Subsection 2.3 and ICOS will reimburse LICENSEE for its reasonable costs and adjudicated claims against
SGI, all arising in this regard. 

    2.4  Delivery of Materials.  Within [*] ([*])
[*] after request by LICENSEE, ICOS shall deliver to LICENSEE the materials listed in Exhibit B. The materials shall be used in compliance with this Agreement and may
not be conveyed to other parties except for sublicensees as described herein. 

  ARTICLE 3—CONSIDERATION         

    3.1  Milestone Payments.  Within thirty (30) days following the first achievement by LICENSEE, its
affiliates or its sublicensees of the following milestones with respect to each Licensed Product, LICENSEE shall pay to ICOS the applicable payments below: 

	3.1.1
	LICENSEE
shall pay to ICOS $[*] U.S. ([*] U.S. Dollars) upon approval to commence a
[*] or instead at ICOS discretion, a [*].

	3.1.2
	LICENSEE
shall pay to ICOS $[*] U.S. ([*] U.S. Dollars) upon [*].

	3.1.3
	LICENSEE
shall pay to ICOS $[*] U.S. ([*] U.S. Dollars) upon [*]. 

    3.2  Royalties.  LICENSEE shall pay to ICOS a royalty of [*]% on all Net Sales of
any Licensed Product (the "Royalty Rate") provided, however, that the Royalty Rate shall be [*]% for any Licensed Product
utilizing BR96. Notwithstanding the foregoing, in the event of a Change in Control of Licensee, the Royalty Rate with respect to Licensed Products for which development is to commence after the
consummation of the Change in Control shall be [*]% or the median royalty rate in all other license agreements of ICOS then in effect under which ICOS has licensed any of the
Patent Rights solely and is receiving royalties, but in no event shall the Royalty Rate be [*]%. 

    3.3  One Royalty.  No more than one royalty payment shall be due with respect to a sale of a particular
Licensed Product. No multiple royalties shall be payable because any Licensed Product, or its manufacture, sale or use is covered by more than one Valid Claim. 

    3.4  Sublicensing Obligations.  Whenever LICENSEE sublicenses any rights hereunder it shall promptly
notify ICOS of the scope of the sublicense, the sublicensee' s name and address and the description of the Licensed Product to which the sublicense pertains. LICENSEE shall remain responsible for the
sublicensee's compliance with the terms of this Agreement and shall remain responsible for paying and reporting all royalties and milestone payments due hereunder as if the milestones and sales of
Licensed Products by sublicensee were those of LICENSEE, i.e., LICENSEE shall pay all royalties set forth in 3.2 with respect to Net Sales of Licensed Products by sublicensee, report all such sales
and pay the milestone payments set forth in Section 3.1 upon the achievement of the milestones by the sublicensee. 

3

  ARTICLE 4—PAYMENTS; REPORTS AND RECORDS         

    4.1  Payments: Currency.  All payments due hereunder shall be paid by wire transfer in United States
dollars in immediately available funds to an account designated by ICOS. If any currency conversion shall be required in connection with the payment of any royalties hereunder, such conversion shall
be made by using the exchange rate for the purchase of U.S. dollars quoted in the U.S. version of the Wall Street Journal on the last business day of the calendar quarter to which such royalty
payments relate. 

    4.2  Royalty Reports and Payments.  After the first commercial sale of a Licensed Product on which
royalties are required to be paid hereunder, LICENSEE shall make quarterly written reports to ICOS within [*] ([*]) [*] after
the end of each calendar quarter, stating in each such report, by country, the number, description, and aggregate Net Sales of each Licensed Product sold during the calendar quarter, ICOS shall treat
all such reports as Confidential Information of LICENSEE. Concurrently with the making of such reports, LICENSEE shall pay ICOS the royalties specified in Section 3.3 hereof. 

    4.3  Records: Inspection.  LICENSEE shall keep complete, true and accurate books of account and records
for the purpose of determining the royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of LICENSEE for at least
[*]([*]) [*] following the end of the calendar quarter to which they pertain and will be available for inspection during such
period by a representative of ICOS for the purpose of verifying the royalty reports and payments. Such inspections shall be made during ordinary business hours. The representative may be obliged to
execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section 4.3 shall be at the expense of ICOS, unless an underpayment
exceeding [*] percent ([*]%) of the amount stated for any period covered by the inspection is identified, in which case all costs relating to the
inspection will be paid immediately by LICENSEE. Any underpayments or unpaid amounts discovered by such inspections or otherwise will be paid immediately by LICENSEE, with interest from the date
(s) such amount (s) were due at the prime rate reported in the Wall Street Journal plus [*] percent ([*]%). 

  ARTICLE 5—DILIGENCE         

    5.1  Reasonable Efforts.  LICENSEE agrees to use reasonable efforts consistent with its prudent business
judgment to diligently develop and commercialize the Patent Rights and obtain such approvals as may be necessary for the sale of the Licensed Products in the United States and such other worldwide
markets as LICENSEE elects to commercialize the Licensed Products. 

    5.2  Reports to ICOS.  During the term of this Agreement, for all products which are produced for
commercial manufacture using the Licensed Technology and for any modification of the transcriptional regulating sequences claimed by the Licensed Patent; LICENSEE shall keep ICOS reasonably informed
of its activities subject to this Agreement, including the achievement of the milestones set forth in Section 3.1 for the commercialization of each Licensed Product. "Reasonably informed" for
the purposes of this Section 5.2 shall mean at least once per calendar year and more often if the reported events will affect the duties of the LICENSEE under this Agreement. When the
registration package requesting approval for commercial sale of each Licensed Product is first filed in each of the U.S., Europe and Japan, and in each case when approval is received therefor,
LICENSEE will promptly notify ICOS. LICENSEE shall notify ICOS within [*] ([*]) [*] after the first commercial sale of each
Licensed Product. 

  ARTICLE 6—CONFIDENTIALITY         

    6.1  Confidential Information.  Except as expressly provided herein, the parties agree that, for the term
of this Agreement and for [*] ([*]) [*] thereafter, the receiving party shall keep completely confidential and shall not publish
or otherwise disclose and shall not use for any purpose except for the 

4

purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing party hereto, except that to the extent that it can be established by the receiving party by
written proof that such Confidential Information: 

	(a)
	was
already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

	(b)
	was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

	(c)
	became
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of
this Agreement; or

	(d)
	was
subsequently lawfully disclosed to the receiving party by a person other than a party hereto. 

    6.2  Permitted Use and Disclosures.  Each party hereto may use or disclose information disclosed to it by
the other party to the extent such use or disclosure is reasonably necessary in complying with applicable law or governmental regulations or conducting clinical trials; provided that if a party is
required to make any such disclosure of another party's Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter party of such
disclosure and, will use its reasonable best efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). 

    6.3  Confidential Terms.  Except as expressly provided herein, each party agrees not to disclose any
terms of this Agreement to any third party without the consent of the other party; provided, disclosures may be made as required by securities or other applicable laws, or to actual or prospective
corporate partners, or to a party's accountants, attorneys and other professional advisors. 

    6.4  Agreement Announcement.  The parties hereby agree that fact of the consummation of this Agreement
and its general subject matter shall be deemed to be in the public domain and may be announced or otherwise referred to, subject to the prior approval of each party of the form of any such press
release or public announcement, but that the specific terms and conditions herein shall be Confidential Information of each party. 

  ARTICLE 7—REPRESENTATIONS AND WARRANTIES         

    7.1  Representations and Warranties.  ICOS represents and warrants that at the time of entering into this
Agreement: (a) it is the sole and exclusive owner of all right, title and interest in the Patent Rights; and (b) it has the right to grant the license granted herein. 

    7.2  Disclaimer.  Nothing in this Agreement is or shall be construed as: 

	(a)
	A
warranty or representation by ICOS as to the validity or scope of any claim or patent within the Patent Rights;

	(b)
	A
warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of any patent
rights or other intellectual property right of any third party;

	(c)
	An
obligation to bring or prosecute actions or suits against third parties for infringement of any of the Patent Rights or misappropriation of any Know-How; or

	(d)
	Granting
by implication, estoppel, or otherwise any licenses or rights under patents or other rights of ICOS or third parties, regardless of whether such patents or other rights
are dominant or subordinate to any patent within the Patent Rights. 

5

    7.3  No Warranties.  EXCEPT AS SET FORTH IN SECTION 7.1, ICOS GRANTS NO WARRANTIES WITH RESPECT TO THE
LICENSED TECHNOLOGY, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUE OR OTHERWISE, AND ICOS SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, VALIDITY OF THE PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 

  ARTICLE 8—INDEMNIFICATION         

    8.1  By LICENSEE.  LICENSEE agrees to indemnify, defend and hold ICOS and its directors, officers,
employees and agents harmless from and against any and all liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees, other costs of litigation and
including the costs of establishing the right to indemnify), losses or causes of action (each, a "Liability") arising out of or relating in any way to (i) the possession, manufacture use, sale
or other disposition of Licensed Products, whether based on breach of warranty, negligence, product liability or otherwise, (ii) the
exercise of any right granted to LICENSEE pursuant to this Agreement, or (iii) any breach of this Agreement by LICENSEE, except to the extent, in each case, that such Liability is caused by the
negligence (active, passive or imputed) or willful misconduct of ICOS as determined by a court of competent jurisdiction. 

    8.2  By ICOS.  ICOS agrees to indemnify, defend and hold LICENSEE and its directors, officers, employees
and agents harmless from and against any and all liabilities, claims, demands, expenses (including, without limitation, attorneys and professional fees, other costs of litigation and including the
costs of establishing the right to indemnify), losses or causes of action (each, a "Liability") arising out of or relating in anyway to breach of any of ICOS's representations and warranties made
under Section 7.1 of this Agreement. 

  ARTICLE 9—TERM AND TERMINATION         

    9.1  Term.  The term of this Agreement will commence on the Effective Date and remain in full force and
effect until the expiration of the last patent within the Patent Rights, unless earlier terminated in accordance with this Article 9. 

    9.2  Permissive Termination.  LICENSEE may terminate this Agreement at any time by providing ICOS notice
in writing at least [*]([*]) [*] prior to the effective date of termination. 

    9.3  Termination for Cause.  Either party may terminate this Agreement in the event the other party has
materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for [*] ([*])
[*] after written notice thereof was provided to the breaching party by the non-breaching party. Any termination shall become effective at the end of such
[*]([*]) [*] period unless the breaching party has cured any such breach or default prior to the expiration of such period.
Notwithstanding the above, in the case of a failure to pay any amount due hereunder the period for cure of any such default following notice thereof shall be [*]
([*]) [*] and, unless payment is made within such period, the termination shall become effective at the end of such period. 

    9.4  Termination for Insolvency.  If voluntary or involuntary proceedings by or against a, party are
instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for such party, or proceedings are instituted by or against such party for corporate reorganization or the
dissolution of
such party, which proceedings, if involuntary, shall not have been dismissed within [*] ([*]) [*] after the date of filing, or
if such party makes an assignment for the benefit of creditors, or substantially all of the assets of such party are seized or attached and not released within [*]
([*]) [*] thereafter, the other party may immediately terminate this Agreement effective upon notice of such termination. 

6

    9.5  Effect of Termination.  

	(a)
	Accrued Rights and Obligations.  Termination of this Agreement for any reason shall not release any party hereto from
any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any
breach of this Agreement and that the non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to be the exclusive remedy
for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity.

	(b)
	Return of Confidential Information.  Upon any termination of this Agreement, LICENSEE and ICOS shall promptly return
to the other party all Confidential Information, (except ICOS may retain copies of any reports or records subject to Article 4).

	(c)
	Stock on Hand.  In the event this Agreement is terminated for any reason, LICENSEE shall have the right to sell or
otherwise dispose of the stock of any Licensed Product then on hand until [*], subject to Articles 3 and 4 and the other applicable terms of this Agreement.

	(d)
	Licenses.  All licenses granted hereunder shall terminate upon the termination of this Agreement. 

    9.6  Survival.  Articles 3, 4, 6, 7, 8 and Sections 9.5 and 9.6 and any Section of 10 that have continued
obligation of this Agreement shall survive the expiration or termination of this Agreement for any reason and any Definition of Section 1 required to interpret such surviving provisions. 

  ARTICLE 10—MISCELLANEOUS PROVISIONS         

    10.1  Governing Law: Venue.  This Agreement and any dispute, including without limitation any
arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of Washington and the United States of America,
without reference to conflicts of laws principles. The exclusive venue of any dispute arising out of or in connection with the performance or breach of this Agreement shall be the state or federal
courts in King County, Washington, and the parties hereby consent to the personal jurisdiction of such courts. 

    10.2  Assignment.  LICENSEE may not transfer or assign this Agreement or any of LICENSEE's rights
hereunder without the written consent of ICOS, except that LICENSEE may assign such rights or duties without such consent in connection with any merger,
consolidation, or any sale of all or substantially all of its assets. Any such attempted or constructive transfer or assignment other than the foregoing shall be void. ICOS may assign this Agreement
or its rights hereunder. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 

    10.3  Waiver.  No waiver of any rights shall be effective unless expressly consented to in writing by the
party to be charged and the waiver of any breach of default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 

    10.4  Severability.  In the event that any provisions of this Agreement are determined to be invalid or
unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 

    10.5  Notices.  All notices, requests and other communications hereunder shall be in writing and shall be
personally delivered or sent by telecopy or other electronic facsimile transmission or by 

7

registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other
parties hereto: 

	LICENSEE:	 	 
	 	 	Attn: H. Perry Fell, CEO

Company: Seattle Genetics, Inc.

Address: 22215 26th Avenue S.E. Suite 300

Bothell,WA 98021

Phone: 425-489-4990

Facsimile: 425-489-4798
	 

ICOS:	 
 	 

 
	 	 	Legal Department

ICOS Corporation

22021 20th Avenue S.E.

Bothell, WA 98021

Phone: 425-485-1900

Facsimile: 425-398-8950

    10.6  Independent Contractors.  Both parties are independent contractors under this Agreement. Nothing
contained in this Agreement is intended nor is to be construed so as to constitute ICOS or LICENSEE as partners or joint venturers with respect to this Agreement. Neither party shall have any express
or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any
third party. 

    10.7  Compliance with Laws.  In exercising their rights under this license, the parties shall fully
comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this
Agreement. LICENSEE shall be responsible, at its expense, for making any required registrations or filings with respect to this Agreement and obtaining any necessary governmental approvals with
respect hereto. 

    10.8  Use of Name.  Neither party shall use the name or trademarks of the other party for any purpose,
including, but not limited to, press releases without the prior written consent of such other party (except as set forth in Section 6.4 above). 

    10.9  Further Actions.  Each party agrees to execute, acknowledge and deliver such further instruments,
and do such other acts, as may be necessary and appropriate in order to carry out the purposes and intent of this Agreement. 

    10.10  Entire Agreement Amendment.  This Agreement constitutes the entire and exclusive Agreement between
the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof. No amendment or addition to this
Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 

8

    IN WITNESS WHEREOF, ICOS and LICENSEE have executed this Agreement in duplicate originals by duly authorized officers. 

	ICOS CORPORATION	 	SEATTLE GENETICS, INC.
	 

By:	 
 	 

/s/ GARY WILCOX
	 
 	 

By:	 
 	 

/s/ H. PERRY FELL

	 

Name:	 
 	 

Gary Wilcox
	 
 	 

Name:	 
 	 

H. Perry Fell

	 

Title:	 
 	 
 EVP, Operations
	 
 	 

Title:	 
 	 
 C.E.O.

	 

Date:	 
 	 

10/16/00
	 
 	 

Date:	 
 	 

10/16/00

	 

 	 
 	 

 	 
 	 

 	 
 	 

 

9

QuickLinks

CONTRACT MANUFACTURING AGREEMENT

APPENDIX E Price and Payment Terms

APPENDIX G NON-EXCLUSIVE LICENSE AGREEMENT

BACKGROUND

ARTICLE 1—DEFINITIONS

ARTICLE 2—LICENSE

ARTICLE 3—CONSIDERATION

ARTICLE 4—PAYMENTS; REPORTS AND RECORDS

ARTICLE 5—DILIGENCE

ARTICLE 6—CONFIDENTIALITY

ARTICLE 7—REPRESENTATIONS AND WARRANTIES

ARTICLE 8—INDEMNIFICATION

ARTICLE 9—TERM AND TERMINATION

ARTICLE 10—MISCELLANEOUS PROVISIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]